Clinical Trial Update: Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes [Phase 2]

View source ↗

Summary

TAK-442 was evaluated in a Phase 2 trial in patients with Acute Coronary Syndrome to assess safety and efficacy. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• TAK-442

Snippet

Sponsor: Takeda | Conditions: Acute Coronary Syndrome | Phase 2 | Status: COMPLETED